23 Aug Targeting a Lower Systolic Blood Pressure Likely To Be Well Tolerated, Even In Elderly
MedicalResearch.com Interview with:
Dan Berlowitz, MD, MPH
Chief of Staff, Edith Nourse Rogers Memorial VA Hospital
Professor, Boston University Schools of Public Health and Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The main results from the SPRINT study, published in 2015, demonstrated that intensive hypertension therapy targeting a systolic blood pressure (SBP) of 120 mm Hg results in reduced cardiovascular morbidity and mortality when compared to standard therapy targeting a SBP of 140. Yet many have expressed concerns that lowering SBP to 120 may be associated with a variety of symptoms, including dizziness, fatigue, and depression, especially in older and frailer patients.
This study using SPRINT data examined patient-reported outcomes including health-related quality of life, depressive symptoms, and satisfaction.
The main findings are that there were no differences in patient-reported outcomes among patients receiving intensive therapy compared to standard therapy, even among older SPRINT participants with multiple comorbidities.
MedicalResearch.com: What should clinicians and patients take away from your report?
Response: Active hypertension management targeting a lower systolic blood pressure is likely to be well tolerated by patients, even those over age 75 and with multiple comorbidities.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: There needs to be research on new strategies to implement these recommendations for a lower blood pressure target.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
N Engl J Med 2017; 377:733-744
August 24, 2017DOI: 10.1056/NEJMoa1611179
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.